Tumor Growth and Tumor Radiosensitivity in Mice Given Myeloprotective Doses of Fibroblast Growth Factors

Ding, Ivan; Huang, Kundi; Snyder, Matthew L.; Cook, John A.; Zhang, Lurong; Wersto, Nancy; Okunieff, Paul

doi:10.1093/jnci/88.19.1399

Cited by 17 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, no studies to date have provided any evidence of malignant transformation resulting from the use of supplemental growth factors when no preexisting genetic mutation exists. When tumors were implanted in mice given supplemental bFGF, no statistical increase in tumor growth rates was seen 49 . Furthermore, no clinical study has shown increased propensity to keloid or hypertrophic scar formation with growth factor therapy.…”

Section: Discussionmentioning

confidence: 99%

Improving Surgical Wound Healing with Basic Fibroblast Growth Factor after Radiation

et al. 2005

View full text Add to dashboard Cite

Decreased local levels of bFGF in skin may play an important role in the delayed healing of irradiated wounds. Radiation appears to decrease bFGF production by significantly reducing bFGF message in irradiated tissue. Supplemental intravenous bFGF reduced irradiated soft tissue injury and improved random skin flap viability in this porcine model. More studies are needed to investigate the effects of bFGF in the surgical healing of irradiated wounds.

show abstract

Section: Discussionmentioning

confidence: 99%

Improving Surgical Wound Healing with Basic Fibroblast Growth Factor after Radiation

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In many studies, the authors and others have found that FGF-P and FGF-2 mitigate radiation-induced damage to the bone marrow, small bowel, and skin and can improve the bone growth of irradiated juvenile murine femurs (Okunieff et al 1995(Okunieff et al , 1999(Okunieff et al , 2001(Okunieff et al , 2007Ding et al 1996Ding et al , 1997Ding et al , 2002Ding et al , 2003Wang et al 1998;Zhang et al 2010Zhang et al , 2011Budiraharjo et al 2013;Ma et al 2013;Shi et al 2013). Randomized studies in humans using bovine FGF-2 have demonstrated improved healing of ischemic wounds for patients with diabetes and burns at graft and donor sites (Fu et al 1998(Fu et al , 2000.…”

Section: Discussionmentioning

confidence: 99%

A Basic Fibroblast Growth Factor Analog for Protection and Mitigation against Acute Radiation Syndromes

Casey-Sawicki¹,

Zhang²,

Kim³

et al. 2014

Health Physics

Self Cite

View full text Add to dashboard Cite

The effects of fibroblast growth factors and their potential as broad-spectrum agents to treat and mitigate radiation injury have been studied extensively over the past two decades. This report shows that a peptide mimetic of basic fibroblast growth factor (FGF-P) protects and mitigates against acute radiation syndromes. FGF-P attenuates both sepsis and bleeding in a radiation-induced bone marrow syndrome model and reduces the severity of gastrointestinal and cutaneous syndromes; it should also mitigate combined injuries. FGF-2 and FGF-P induce little or no deleterious inflammation or vascular leakage, which distinguishes them from most other growth factors, angiogenic factors, and cytokines. Although recombinant FGFs have proven safe in several ongoing clinical trials, they are expensive to synthesize, can only be produced in limited quantity, and have limited shelf life. FGF-P mimics the advantageous features of FGF-2 without these disadvantages. This paper shows that FGF-P not only has the potential to be a potent yet safe broad-spectrum medical countermeasure that mitigates acute radiotoxicity but also holds promise for thermal burns, ischemic wound healing, tissue engineering, and stem-cell regeneration.

show abstract

“…Pre-clinical studies demonstrate that FGFs given in almost any schedule beginning 48 h before irradiation to 24 h after irradiation, can reduce haematopoietic toxicity, 19,[21][22][23][24][25][26] small bowel crypt stem cell loss, 14,15 pulmonary radiosensitivity, 16,17,31,32 and bone growth defects after irradiation. 5,18,33 Other FGF isoforms can also radioprotect in a variety of circumstances.…”

Section: Discussionmentioning

confidence: 99%

“…The time periods before and after completion of TBI were chosen based on pre-clinical data demonstrating a radioprotective effect of bFGF during those periods. 19,[21][22][23][24][25][26] Daily blood samples collected during the week following the reinfusion of marrow suggest that marrow reinfusion has no significant effect on plasma bFGF concentrations. After collection in EDTA, plasma was briefly stored on ice, centrifuged at 3000 g for 30 min and aliquoted for later analysis.…”

Section: Methodsmentioning

confidence: 99%

Circulating basic fibroblast growth factor declines during Cy/TBI bone marrow transplantation

Okunieff

Barrett

Phang

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Basic fibroblast growth factor (bFGF) inhibits radiation-induced apoptosis, and radioprotects haematopoietic, cartilage growth plate, pulmonary and gastrointestinal tissues. Conversely, chronic overexpression of bFGF may promote fibrosis. We measured the endogenous circulating bFGF in blood of patients undergoing conditioning TBI. Twenty-six patients with haematopoietic malignancies were conditioned with cyclophosphamide/TBI for allogeneic BMT. Daily blood samples were collected each morning prior to, during, and for several days after TBI. bFGF levels in plasma of normal volunteers are 0.8-26 pg/ml. bFGF was below detectability in 22%, 30% and 45% of patients pre-TBI, during TBI or post-TBI respectively. Mean circulating plasma levels of bFGF decreased from a median of 52 pg/ml pre-TBI to 26 pg/ml during TBI, and to 5 pg/ml post-TBI. Among the 26 patients, 13 had more than one non-detectable plasma bFGF level, an additional five had at least one non-detectable level, and only eight patients had detectable levels in all daily samples. Naturally high levels of bFGF were observed in some patients undergoing fractionated TBI. In contrast, as many as 79% of patients had low bFGF levels in one or more samples. The impact of endogenous bFGF on the tolerance of normal tissues to irradiation is unknown, and warrants further study.

show abstract

Tumor Growth and Tumor Radiosensitivity in Mice Given Myeloprotective Doses of Fibroblast Growth Factors

Abstract: Low intravenous doses of FGF1 or FGF2 appear to protect bone marrow from the toxic effects of radiation without increasing the rates of tumor growth or metastases or decreasing the radiosensitivity of tumors.

Cited by 17 publications

References 13 publications

Improving Surgical Wound Healing with Basic Fibroblast Growth Factor after Radiation

Improving Surgical Wound Healing with Basic Fibroblast Growth Factor after Radiation

A Basic Fibroblast Growth Factor Analog for Protection and Mitigation against Acute Radiation Syndromes

Circulating basic fibroblast growth factor declines during Cy/TBI bone marrow transplantation

Contact Info

Product

Resources

About